Paper Details

  1. Home
  2. Paper Details

Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.

Author: , BloemBas R, BoelJudith A, DeuschlGuenther, DijkgraafMarcel G W, LangAnthony E, MuntsAlexander G, PostBart, SuwijnSven R, TissinghGerrit, VerschuurConstant V M, de BieRob M A, de HaanRob J, van HiltenJohannes J, van LaarTeus

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This double-blind, placebo-controlled trial of 445 patients with early Parkinson's disease evaluated the disease-modifying effect of levodopa. The study found no significant difference between early-start and delayed-start groups in the Unified Parkinson's Disease Rating Scale score at week 80, suggesting that levodopa does not have a disease-modifying effect. Further research is needed to determine the optimal timing for initiating levodopa treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated. METHODS: In a multicenter, double-blind, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1809983

データ提供：米国国立医学図書館（NLM）

Levodopa for Parkinson's Disease: A Timely Oasis in a Desert of Symptoms

Parkinson's disease, a neurodegenerative disorder, can feel like navigating a desert of tremors and stiffness. This study investigates the timing of levodopa treatment for Parkinson's disease, exploring whether early initiation can have a disease-modifying effect. Researchers are like experienced desert guides, seeking to find the optimal path for patients facing this challenging condition.

Early vs. Delayed Treatment: A Search for the Right Oasis

This randomized controlled trial compared the effects of early-start levodopa treatment with delayed-start treatment. The researchers found that levodopa did not have a disease-modifying effect, meaning it did not slow down the progression of Parkinson's disease. It's like finding a small oasis in the desert, providing relief from the symptoms but not changing the overall landscape of the disease. This finding highlights the need for ongoing research to explore new ways to modify the course of Parkinson's disease.

Health Implications and Life Applications

This study underscores the importance of discussing treatment options with healthcare providers and making informed decisions about the timing of levodopa therapy. While levodopa remains an effective symptomatic treatment for Parkinson's disease, it's crucial to explore other strategies to potentially slow down disease progression. It's like finding a balance between managing the immediate challenges of the desert while also seeking a way to reshape the landscape for the future.

Dr.Camel's Conclusion

This research reminds us that navigating the desert of Parkinson's disease requires a multifaceted approach. While levodopa provides valuable relief, the search for disease-modifying treatments continues. By understanding the limitations of current therapies and embracing innovation, we can hope to find new oases of hope for patients facing this challenging condition.

Date :
  1. Date Completed 2019-02-07
  2. Date Revised 2019-02-15
Further Info :

Pubmed ID

30673543

DOI: Digital Object Identifier

10.1056/NEJMoa1809983

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.